The latest update is out from Syros Pharmaceuticals (SYRS).
At Syros Pharmaceuticals’ 2024 Annual Meeting, stockholders greenlit a significant amendment to the Equity Incentive Plan, adding 1,750,000 shares for issuance. Additionally, they voted for the election of three Class II directors and passed several other key proposals, including a substantial increase in authorized capital stock and an update to incorporate new Delaware law provisions for officer exculpation. Shareholders also ratified the appointment of Ernst & Young LLP as the auditor for the upcoming fiscal year and endorsed the executive officers’ compensation on an advisory basis.
Learn more about SYRS stock on TipRanks’ Stock Analysis page.
